GLP-1 Cost Management: Research & Analysis for Benefits Teams

The sticker price doesn't tell the story. How rebates, PBM contracts, and utilization patterns create a cost picture most benefits teams aren't seeing clearly.

A growing number of self-insured employers are restricting or removing GLP-1 weight management coverage. What's driving the decisions, and what they're replacing it with.

Real-world persistence data shows most GLP-1 users discontinue before reaching the 12-week minimum for clinically meaningful weight loss. You're paying for prescriptions that never had a chance.

Discontinuation isn't just lost spend — it's weight regain that erodes every dollar you invested. What the clinical trial and real-world data show about post-GLP-1 trajectories.

Coaching programs can work — but cost scales linearly with enrollment. When you run the numbers on offering them to your full eligible population, the economics break down.

Oral formulations will remove the last friction point keeping utilization in check. More convenience means more prescriptions, more spend, and the same discontinuation problem.

If even a fraction of members respond to a first-line program, the pharmacy savings dwarf the program cost. A straightforward financial model any CFO can follow.

Not all step-therapy programs are equal. The clinical criteria that separate evidence-based first-line interventions from checkbox compliance programs.

How to frame the GLP-1 cost discussion for your finance team — including the numbers, the risk scenarios, and the decision framework that actually moves the conversation forward.

Most weight loss interventions are evaluated at 6 or 12 months. What happens at 2 years — and why durability should be the first question you ask any vendor.